Cordant, Inc. Crispr Therapeutics Ag Transaction History
Cordant, Inc.
- $192 Billion
- Q1 2025
A detailed history of Cordant, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Cordant, Inc. holds 114 shares of CRSP stock, worth $5,044. This represents 0.0% of its overall portfolio holdings.
Number of Shares
114Holding current value
$5,044% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
480Shares Held
64.2MCall Options Held
2.15MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$450 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$269 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$168 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$123 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.54MShares$112 Million0.06% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.45B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....